Related Experiment Videos
[Clinical evaluation of the antidepressive agent noveril]
Farmakologiia I Toksikologiia
|May 1, 1982
Summary
Noveril, an activation antidepressant, showed significant improvement in 46% of patients with depressive states. Recommended doses are 160-240 mg, but caution is advised for patients with blood pressure fluctuations.
Area of Science:
- Psychiatry and Pharmacology
- Clinical Therapeutics
Context:
- Depression is a prevalent mental health disorder requiring effective pharmacological interventions.
- Assessing the efficacy and safety of novel antidepressant medications is crucial for clinical practice.
Purpose:
- To evaluate the therapeutic effects and optimal dosage of noveril in patients with various depressive states.
- To identify patient populations that may benefit from or experience adverse effects with noveril treatment.
Summary:
- A study involving 32 patients with depressive states assessed the efficacy of noveril at doses ranging from 160 to 320 mg.
- Complete remission or considerable improvement was observed in 46% of patients, with slight improvement in 38%.
- Noveril demonstrated rapid therapeutic effects, particularly in classical, adynamic, obsessional, and cyclothymic depressions, at doses of 160-240 mg.
Impact:
- Noveril is identified as a potentially effective activation antidepressant with a rapid onset of action.
- The study highlights the need for caution in patients with arterial pressure fluctuations and suggests ineffectiveness or worsening of symptoms in senesthopathic and hypochondriac conditions.